Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy.

Steven P Lee

Journal: Seminars in cancer biology 2003;12(6):463-71

PMID: 12450732

Full Text on Elsevier Science View on PubMed

Abstract

T cells specific for Epstein-Barr virus (EBV) can effectively target the virus-transformed B lymphoproliferative lesions that arise in immunosuppressed transplant patients. This review explores the possibility of developing similar T cell-based strategies to treat an EBV-positive epithelial tumour, nasopharyngeal carcinoma (NPC), which arises in relatively immunocompetent individuals and where EBV antigen expression in the tumour is more limited.

Address: Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. [email protected]

DOI: 10.1016/s1044-579x(02)00089-5

Link outs

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1044...

MeSH Terms: Amino Acid Sequence, Antigen Presentation, Epitopes, T-Lymphocyte, Epstein-Barr Virus Nuclear Antigens, Herpesvirus 4, Human, Humans, Immunotherapy, Adoptive, Molecular Sequence Data, Nasopharyngeal Neoplasms, T-Lymphocytes